myTomorrows

"Every person living with a serious disease deserves to know their options." [1]

Where it wins

• Patient Navigation: Dedicated Patient Navigators pre-screen patients and guide them through the complex process of clinical trial enrollment and expanded access requests [1].
• Dual-Sided Platform: Acts as a connected hub that simultaneously empowers patients to discover treatments and supports BioPharma companies with recruitment, expanded access management, and Real-World Data (RWD) collection [1].
• Global Expanded Access Expertise: Provides specialized, full-service management for Expanded Access Programs (EAPs) and Compassionate Use requests, bridging the gap between patients and trials [1].

Credibility: The platform's core promise and patient navigation model are detailed on the myTomorrows homepage, which outlines the specific services for patients, healthcare professionals, and BioPharma companies [1].

• Service-Based Revenue: Primarily generates revenue through specialized services (recruitment, EAP management, RWD) rather than simple software licensing [1].
• Platform as a Hub: Operates a connected digital platform that facilitates interactions between patients, physicians, and BioPharma companies, scaling access globally [1].
• Human-in-the-Loop: Combines technology with hands-on support via Patient Navigators and experts to manage complex, high-touch processes like trial enrollment and EAPs [1].
• Global Reach: Leverages a network of experts to help patients in almost 50 countries, indicating a scalable international service model [1].

• Specialized Patient Navigation Services: Competes with other patient navigation firms by offering a technology-enabled, global platform with deep BioPharma integration [1].
• Clinical Trial Recruitment Platforms: Differentiates through its dual focus on patient empowerment and BioPharma services, including expanded access management [1].
• Expanded Access Management Providers: Leads with its full-service EAP management and purpose-built platform, addressing a niche but critical need [1].
• Differentiators: The combination of patient navigation, global reach, and comprehensive BioPharma services (recruitment, EAP, RWD) creates a unique value proposition [1].

• Complex Treatment Access: Patients and physicians face a "shockingly slow & complicated process" to access treatments in development [1].
• Limited Patient Awareness: Patients often lack knowledge of all possible treatment options, including clinical trials and expanded access programs [1].
• Recruitment Challenges: BioPharma companies struggle with efficient patient recruitment for clinical trials [1].
• Fragmented Expanded Access: The process for Expanded Access Programs and Compassionate Use is difficult to navigate for patients and providers [1].

myTomorrows has carved a niche at the intersection of patient support and BioPharma services, leveraging a high-touch model that scales through technology. The main risk is the reliance on complex, regulated processes like expanded access, which can be volatile. However, the integration of Real-World Data (RWD) services offers a significant opportunity to provide valuable insights to Pharma, potentially creating a more predictable revenue stream. The next signal to watch is the adoption of their Expanded Access Management Platform by trial sites, which would indicate deeper ecosystem integration and reduced friction in the access process.

myTomorrows should aggressively market its Real-World Data (RWD) services to BioPharma partners, positioning it as a key differentiator beyond just recruitment and access. Expanding the patient navigation model to more therapeutic areas beyond the currently highlighted ones (like lung cancer and rare diseases) could unlock new patient segments. Developing a more robust self-service portal for patients could reduce the operational burden on navigators while maintaining the high-touch support for complex cases. Finally, enhancing the transparency features of the Expanded Access Management Platform could further strengthen trust with healthcare professionals and trial sites.